MedDataX Logo

Trial Outcomes & Findings for Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1) (NCT NCT00947011)

NCT ID: NCT00947011

Last Updated: 2017-07-12

Results Overview

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

12 participants

Primary outcome timeframe

One year

Results posted on

2017-07-12

Participant Flow

Although 12 participants were enrolled in this study, their assignment to a specific Arm/Group is unknown, as the PI has left the institution and no further data (if any) is available.

Participant milestones

Participant milestones
Measure
All Participants
Januvia: 1 tablet 100 mg once a day OR Placebo comparator
Overall Study
STARTED
12
Overall Study
COMPLETED
0
Overall Study
NOT COMPLETED
12

Reasons for withdrawal

Reasons for withdrawal
Measure
All Participants
Januvia: 1 tablet 100 mg once a day OR Placebo comparator
Overall Study
Study was terminated,PI left institution
12

Baseline Characteristics

Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Particpants
n=12 Participants
Januvia: 1 tablet 100 mg once a day OR Placebo: 1 tablet 100 mg once a day
Age, Customized
>=21 and <=75
12 participants
n=5 Participants
Sex: Female, Male
Female
5 Participants
n=5 Participants
Sex: Female, Male
Male
7 Participants
n=5 Participants
Region of Enrollment
United States
12 participants
n=5 Participants

PRIMARY outcome

Timeframe: One year

Population: Data was not collected for this outcome measure. The study was terminated. The P.I. left the institution.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: one year

Population: Data was not collected for this outcome measure. The study was terminated. The P.I. left the institution.

Outcome measures

Outcome data not reported

Adverse Events

Januvia

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Johns Hopkins University Clinical Trials Program

Johns Hopkins University School of Medicine

Phone: 410-550-6484

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place